Vonicog alfa - Takeda
Alternative Names: BAX 111; Recombinant von Willebrand factor; rVWF; SHP-677; TAK 577; VEYVONDI; VEYVONDI IU; VonvendiLatest Information Update: 29 Feb 2024
At a glance
- Originator Max Delbruck Center for Molecular Medicine
- Developer Takeda
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Von Willebrand factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Von Willebrand disease
Most Recent Events
- 09 Jan 2024 Phase-III clinical trials in Von Willebrand disease (Prevention, In children) in Ireland, Ireland, Norway, Sweden, Spain, France, France, Austria, Netherlands, Italy (IV) (EudraCT2020-003304-13, NCT05582993)
- 15 Dec 2023 Takeda initiates an expanded-access programme for Von Willebrand Disease (In children, In adults, In the elderly) (IV) (NCT06173024)
- 12 Oct 2023 The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopts positive opinion recommending approval of vonicog alfa for Von Willebrand disease (In adults, Prevention) in European Union (IV)